top of page

LATEST NEWS

Approved Marine Drugs
Approved Marine Drugs
© 2021-2024 Marine Pharmacology

October 2024

  • All links were checked and working appropriately

  • Clinical trial numbers were updated accordingly

    • Cytarabine: US clinical trials from 410 to 405, European clinical trials from 119 to 115, Japanese clinical trials from 20 to 22, and Chinese clinical trials from 60 to 63

    • Ziconotide: US clinical trials from 2 to 3

    • Omega-3-acid ethyl ester: US clinical trials from 21 to 20

    • Eribulin mesylate: US clinical trials from 73 to 70, European clinical trials from 21 to 20

    • Brentuximab vedotin: US clinical trials from 72 to 70

    • Trabectedin: US clinical trials from 21 to 22, European clinical trials from 20 to 18

    • Polatuzumab vedotin: US clinical trials from 48 to 51

    • Enfortumab vedotin-ejfv: US clinical trials from 37 to 39, Japanese clinical trials from 12 to 13

    • Lurbinectedin: US clinical trials from 29 to 28, European clinical trials from 5 to 4, Japanese clinical trials from 3 to 2, Chinese clinical trials from 0 to 1

    • Disitamab vedotin: US clinical trials from 77 to 78, Chinese clinical trials from 24 to 26

  • Withdrawn

    • Panobinostat: European clinical trials from 5 to 4

    • Belantamab Mafodotin-blmf: European clinical trials from 17 to 14, Japanese clinical trials from 3 to 2
       

August 2024 

  • All links were checked and are working appropriately. 
    NOTE: Clinical trial numbers were updated and may include Phase 3, as well as Phase 2 and Phase 1 if ongoing.  
    o    Cytarabine: US clinical trials from 411 to 410, European clinical trials from 120 to 119, Japanese clinical trials from from 21 to 20, Chinese clinical trials from 57 to 60
    o    Eribulin Mesylate: US clinical trials from 79 to 73, Japanese clinical trials from 6 to 5
    o     Brentuximab vedotin:  US active clinical trials dropped from 73 to 72, Japanese clinical trials from 1 to 2, Chinese clinical trials 1 to 2 
    o    Trabectedin: US clinical trials from 22 to 21
    o    Polatuzumab vedotin:  US clinical trials from 45 to 48, European clinical trials from 12 to 11, Japanese clinical trials from 6 to 4.
    o    Enfortumab vedotin-ejfv: US clinical trials from 34 to 37, European clinical trials from 5 to 4.
    o    Lurbinectedin: US clinical trials from 28 to 29, European clinical trials from 5 to 4.
    o    Disitamab vedotin. Chinese clinical trials from 21 to 24. 
    o    Tisotumab vedotin. US clinical trials from 3 to 4

​

June 2024 

  • All links were checked and are working appropriately. 
    NOTE: Clinical trial numbers were updated and may include Phase 3, as well as Phase 2 and Phase 1 if ongoing.  
    o    Cytarabine: US clinical trials from 415 to 411, European clinical trials from 123 to 120
    o    Omega-3-acid ethyl ester/Lovaza: US active clinical trials rose from 18 to 21.  Europe active clinical trials for “Lovaza” yielded no change in active clinical trials, but a search for “omega-3-acid ethyl ester” yielded a change from none to 1. Japan active clinical trials dropped from 4 to 3.
    o    Omega-3-carboxylic acids/Epanova:  Japan active clinical trials for “Epanova” yielded a change from none to 1
    o    Eribulin Mesylate: US clinical trials from 73 to 79.   Europe active clinical trials dropped from 22 to 21. Chinese active clinical trials rose from 13 to 15 
    o     Brentuximab vedotin:  US active clinical trials dropped from 75 to 73. Chinese active clinical trials rose from 1 to 2 
    o    Trabectedin: US clinical trials from 21 to 22, European clinical trials from 21 to 20.
    o    Plitidepsin: US clinical trials from 1 to 0.
    o    Polatuzumab vedotin:  US clinical trials from 45 to 42, European clinical trials from 13 to 12, Japanese clinical trials from 5 to 6.
    o    Enfortumab vedotin-ejfv: US clinical trials from 32 to 34, Japanese clinical trials from 10 to 12 .
    o    Lurbinectedin: US clinical trials from 27 to 28.
    o    Disitamab vedotin. US clinical trials from 72 to 77, Chinese clinical trials from 19 to 21. 

​

May 2024 

​

April 2024 

  • All links were checked and working appropriately 

  • Clinical trial numbers were updated accordingly

    •  Cytarabine: US clinical trials from 412 to 415, European clinical trials from 124 to 123

    •  Eicosapenta enoic acid ethyl ester: US clinical trials from 5 to 4 

    •  Eribulin Mesylate: US clinical trials from 72 to 73 

    • Brentuximab vedotin:  US clinical trials from 77 to 75 

    • Trabectedin: US clinical trials from 21 to 22, European clinical trials from 21 to 20

    • Polatuzumab vedotin: European clinical trials from 2 to 13, Chinese clinical trials from 1 to 2 

    • Enfortumab vedotin-ejfv: US clinical trials from 30 to 32 

    • Lurbinectedin: Japanese clinical trials from 2 to 3 

    • Disitamab vedotin: Chinese clinical trials from 18 to 19

​

March 2024 

  • All links were checked and working appropriately 

  • Clinical trial numbers were updated accordingly

    • Cytarabine US clinical trials from 415 to 412, European clinical trials from 125 to 124, Chinese clinical trials from 56 to 57 

    • Vidarabine US clinical trials from 21 to 23 

    • Omega-3-acid ethyl esters US clinical trials from 19 to 18, Japanese clinical trials from 3 to 4 

    • Eicosapenta enoic acid ethyl ester US clinical trials from 4 to 5 

    • Eribulin Mesylate US clinical trials from 67 to 72 

    • Brentuximab vedotin US clinical trials from 76 to 77 

    • Trabectedin US clinical trials from 20 to 21 

    • Polatuzumab vedotin Japanese clinical trials from 3 to 5 

    • Enfortumab vedotin-ejfv US clinical trials from 28 to 30 

    • Lurbinectedin US clinical trials from 28 to 27, Japanese clinical trials from 1 to 2 

    • Disitamab vedotin US clinical trials from 71 to 72, Chinese clinical trials from 15 to 18 

​

February 2024 

  • All links were checked and working appropriately 

  • Clinical trial numbers were updated accordingly​

    • Cytarabine US clinical trials from 411 to 415, Japanese clinical trials from 20 to 21, Chinese clinical trials from 55 to 56 

    • Eribulin Mesylate US clinical trials from 68 to 67 

    • Brentuximab vedotin US clinical trials from 77 to 76 

    • Trabectedin European clinical trials from 22 to 21 

    • Polatuzumab vedotin Japanese clinical trials from 4 to 3 

    • Enfortumab vedotin-ejfv US clinical trials from 30 to 28, European clinical trials from 10 to 9 

    • Lurbinectedin US clinical trials from 26 to 28 

    • Disitamab vedotin US clinical trials from 65 to 71, Chinese clinical trials from 14 to 15 

​

January 2024

  • All links were checked and are working appropriately.

  • Clinical trial numbers were updated accordingly.

    • Cytarabine US clinical trials from 422 to 411, Japanese clinical trials from 19 to 20 

    • Vidarabine US clinical trials from 24 to 21 

    • Omega-3-acid ethyl esters US clinical trials from 17 to 19, Japanese clinical trials from 0 to 3 

    • Eicosapenta enoic acid ethyl ester US clinical trials from 7 to 4 

    • Eribulin mesylate Japanese clinical trials from 7 to 6, Chinese clinical trials from 12 to 13 

    • Brentuximab vedotin US clinical trials from 75 to 77, Japanese clinical trials from 2 to 1 

    • Polatuzumab vedotin US clinical trials from 44 to 45, Japanese clinical trials from 3 to 4 

    • Lurbinectedin US clinical trials from 25 to 26 

    • Disitamab vedotin US clinical trials from 60 to 65, Japanese clinical trials from 0 to 1, Chinese clinical trials from 12 to 14 

    • Tisotumab vedotin-tftv US clinical trials from 4 to 3 

​

December 2023 ​ ​

  • All links were checked and are working appropriately.

  • Clinical trial numbers were updated accordingly.

    • Cytarabine US clinical trials from 420 to 422, Japanese clinical trials from 22 to 19, and Chinese clinical trials from 54 to 55

    • Vidarabine US clinical trials from 23 to 24

    • Eribulin mesylate Chinese clinical trials from 10 to 12

    • Brentuximab vedotin US clinical trials from 77 to 75

    • Trabectedin US clinical trials from 21 to 20

    •  Polatuzumab vedotin Chinese clinical trials from 0 to 1

    •  Enfortumab vedotin US clinical trials from 29 to 30 and Japanese clinical trials from 9 to 10

    • Lurbinectedin US clinical trials from 23 to 25

    • Disitamab vedotin US clincal trials from 56 to 60 and Chinese clinical trials from 11 to 12

​

October 2023 ​

  • All links were checked and the Mochida Pharmaceutical link https://www.mochida.co.jp/english/business/mainproducts.html is intermittently giving an error that it "can’t provide a secure connection”. All other links are working as expected.

  • Japanese clinical trials information is being added to the table. https://rctportal.niph.go.jp/en/result

  • Clinical trial numbers were updated accordingly.

    • Cytarabine US clinical trials from 423 to 420, European clinical trials from 127 to 125, and Japanese clinical trials from 23 to 22

    • Brentuximab vedotin US clinical trials from 81 to 77, and European clinical trials from 40 to 39

    • Trabectedin US clinical trials from 20 to 21

    •  Polatuzumab vedotin US clinical trials from 40 to 44

    •  Enfortumab vedotin European clinical trials from 11 to 10

    • Disitamab vedotin US clincal trials from 51 to 56

​

September 2023 ​

  • All links were checked and working properly.

  • Japanese clinical trials information was checked as well.

  • Clinical trial numbers were updated accordingly.

    • Cytarabine US clinical trials from 432 to 423, European clinical trials from 126 to 127, and Japanese clinical trials from 22 to 23

    • Vidarabine US clinical trials from 22 to 23, Japanese clinical trials 5

    • Omega-3-acid ethyl esters US clinical trials from 18 to 17 

    • Eicosapentaenoic acid ethyl esters Japanese clinical trials 2

    • Eribulin mesylate Japanese clinical trials 7 

    • Brentuximab vedotin US clinical trials from 82 to 81 and Japanese clinical trials 2

    • Polatuzumab vedotin US clinical trials from 39 to 40 and Japanese clinical trials 3

    • Enfortumab vedotin US clincal trials from 28 to 29 and Japanese clinical trials from 12 to 9

    • Lurbinectedin US clincal trials from 24 to 23 and Japanese clinical trials 1

    • Disitamab vedotin US clincal trials from 47 to 51 and Chinese clinical trials from 10 to 11

​

August 2023 ​

  • All links were checked and working properly.

  • Japanese clinical trials information was checked as well.

  • Clinical trial numbers were updated accordingly.

    • Cytarabine US clinical trials from 434 to 432, European clinical trials from 127 to 126, and Japanese clinical trials 22

    • Vidarabine US clinical trials from 23 to 22 and Japanese clinical trials 5

    • Eicosapentaenoic acid ethyl esters Japanese clinical trials 2

    • Eribulin Mesylate US clinical trials from 66 to 68 and Japanese clinical trials 7 

    • Brentuximab vedotin US clinical trials from 84 to 82 and Japanese clinical trials 2 

    • Trabectedin US clinical trials from 21 to 20

    • Polatuzumab vedotin US clinical trials from 37 to 39 and Japanese clinical trials 3

    • Enfortumab vedotin US clincal trials from 28 to 29 and Japanese clinical trials 12

    • Lurbinectedin US clincal trials from 24 to 23 and Japanese clinical trials 1

    • Disitamab vedotin US clincal trials from 47 to 51 and Chinese clinical trials from 8 to 10

​

July 2023 ​

  • All links were checked and working properly.

  • Clinical trial numbers were updated accordingly.

    • Cytarabine US clinical trials from 440 to 434 and Chinese clinical trials from 53 to 54

    • Vidarabine US clinical trials from 24 to 23

    • Omega-3-acid ethyl esters US clinical trials from 20 to 18

    • Eicosapentaenoic acid ethyl ester US clinical trials from 4 to 7

    • Eribulin Mesylate US clinical trials from 33 to 66 and Chinese clinical trials from 9 to 10

    • Brentuximab vedotin US clinical trials from 71 to 84 

    • Trabectedin US clinical trials from 19 to 21

    • Polatuzumab vedotin US clinical trials from 25 to 37

    • Enfortumab vedotin US clinical trials from 21 to 28, European clinical trials from 10 to 11, and Chinese clinical trials from none to

    • Lurbinectedin US clinical trials from 23 to 24

    • Disitamab vedotin US clincal trials from 32 to 47 and Chinese clinical trials from 7 to 8

​

June 2023 ​

  • All links were checked and working except the Chinese Clinical Trials links. Chinese clinical trials links were checked for all and updated to:

  • The year-of-FDA-approval link for the Blenrep withdrawal was updated.

  • Panobinostat (Farydak®) and Belantamab Mafodotin-blmf (Blenrep™) were withdrawn​ from accelerated approval and removed from the table. 

  • It was noted in the drug table that Omega-3-carboxylic acid (Epanova®) was discontinued in 2021.

  • The Molecular Target was corrected for Panobinostat to deacetylase, Plitidepsin to eEF1A2, Polutuzumab vedotin to CD79b and microtubules, Enfortumab vedotin-ejfv to Nectin-4 and microtubules, Disitimab vedotin to HER2 and microtubules, and Tisotumab vedotin-tftv to TF and microtubules.

  • Clinical trial numbers were updated accordingly.

    • Cytarabine US clinical trials from 428 to 440 and Chinese clinical trials from 48 to 53.

    • Vidarabine US clinical trials from 23 to 24.

    • Omega-3-acid ethyl esters US clinical trials from 22 to 20.

    • Eribulin mesylate US clinical trials from 35 to 33, European clinical trials from 21 to 22, and Chinese clinical trials from 8 to 9.

    • Trabectedin US clinical trials from 20 to 19.

    • Enfortumab vedotin US clinical trials from 19 to 21 and European clinical trials from 9 to 10.

    • Lurbinectedin US clinical trials from 21 to 23.

    • Belantamab mafodotin US clinical trials from 34 to 39 and European clinical trials from 17 to 19.

    • Disitamab vedotin US clinical trials from 29 to 32 and Chinese clinical trials from 6 to 7.

    • Tisotumab vedotin US clinical trials from 3 to 4.

​

April 2023 ​

  • All links were checked and are working properly. 

    • ​In January we changed Arasena A to the current link, which was not working in early April. At the time of our meeting, it was working again, so we did not to change the link. 

  • Clinical trial numbers were updated accordingly.

    • Cytaribine US clinical trials from 425 to 428, European clinical trials from 125 to 127, and Chinese clinical trials from 47 to 48

    • Vidarabine US clinical trials from 21 to 23

    • Ziconotide US clinical trials from 1 to 2

    • Omega-3-acid ethyl esters US clinical trials from 24 to 22

    • Eicosapentaenoic acid ethyl ester US clinical trials from 5 to 4

    • Eribulun Mesulate US clinical trials from 36 to 35

    • Brentuximab vedotin US clinical trials from 70 to 69, European clinical trials from 39 to 40

    • Trabectedin US clinical trials from 21 to 20, European clinical trials from 23 to 22

    • Panbinostat US clinical trials from 12 to 11

    • Plitidepsin US clinical trials from 2 to 1

    • Polutuzumab vedotin US clinical trials from 23 to 25

    • Enfortumab vedotin US clinical trials from 18 to 19

    • Lurbinectedin European clinical trials from 4 to 5

    • Disitimab vedotin US clinical trials from 28 to 29

​

March 2023 ​

  • All links were checked and are working properly. 

  • Clinical trial numbers were updated accordingly.  

    • Cytaribine US clinical trials from 427 to 425

    • Vidarabine US clinical trials from 22 to 21

    • Ziconitide US Clinical trials from 2 to 1

    • Eicosapentaenoic acid ethyl ester European clinical trials from 4 to 2

    • Brentuximab vedotin US clinical trials from 72 to 70, European clinical trials from 39 to 38

    • Polatuzumab vedotin US clinical trials from 22 to 23

    • Lurbinectedin US clinical trials from 20 to 21

    • Belantamab mafodotin US clinical trials from 33 to 34

    • Disitimab vedotin US Clinical trials from 26 to 28 and Chinese clinical trials from 4 to 6

​

February 2023 ​

  • All links were checked and are working properly. 

  • Clinical trial numbers were updated accordingly.  ​​​

    • Cytarabine US clinical trials went from 426 to 427, European clinical trials from 126 to 125, and Chinese clinical trials from 46 to 47

    • Omega-3-carboxylic acid trials were updated from 8 to 0, accounting only for ongoing studies

    • Erubilin mesylate Chinese clinical trials were updated from 7 to 8

    • Panbinostat US clinical trials were updated from 13 to 12

    • Plitidepsin US clinical trials were updated from 1 to 2

    • Enfortumab vedotin US clinical trials were udated from 19 to 18

    • Lurbinectedin US clinical trials were updated from 21 to 20

​

January 2023 ​

  • All links were checked and working properly except the Arasena A prescription link. The Arasena A link https://www.nlm.nih.gov/pubs/techbull/ja22/ja22_pubchem.html was updated December 16th, and no longer shows the prescribing information. It has been updated to https://www.gnhindia.com/products/nz-drugs/vira-a-solution-for-infusion-200-mg-ml/.

  • Chinese cliinical trials links are again working.

  • Clinical trial numbers were updated accordingly.

    • Cytarabine US clinical trials from 430 to 426, European clincal trials from 128 to 126, and Chinese clinical trials from 45 to 46​

    • Omega-3-acid ethyl esters US clinical trials from 23 to 24

    • Brentuximab vedotin US clinical trials from 73 to 72 and European clinical trials from 40 to 39

    • Panbinostat US clincal trials from 14 to 13 and European clinical trials from 8 to 7

    • Plitidepsin European clinical trials from 2 to 3

    • Polatuzumab vedotin European clinical trials from 3 to 2

    • Enfortumab vedotin US clinical trials from 18 to 19

    • Lurbinectedin US clinical trials from 17 to 21 and European clincal trials from 3 to 4

    • Disitimab vedotin Chinese clinical trials from 3 to 4

December 2022 ​

  • All the links have been checked and were working properly, except links addressing compounds in Chinese clinical trials. We are working with Dr. Jinbo Yang's group to update these links.

  • The approved marine-derived pharmaceutical Belantamab Mafoditin-blmf  (Blenrep) withdrawal process was initiated on 11-22-2022, following the request of the FDA. The agency's request was based on the previously announced outcome of the Phase III DREAMM-3 confirmatory trial, which did not meet the requirements of the FDA accelerated approval regulations. (https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-blenrep-us-marketing-authorisation/).   

  • Clinical trials numbers were updated accordingly. 

    • Cytarabine European clinical trials from 132 to 128​

    • Vidarabine US clinical trials from 48 to 22

    • Omega-3-acid ethyl esters US clinical trials from 24 to 23

    • Erubilin mesylate US clinical trials from 38 to 36

    • Panbinostat US clinical trials from 15 to 14 

    • Polutuzumab vedotin US clinical trials from 23 to 22

    • Belantamab mafodotin US clinical trials from 31 to 33 and European clinical trials from 14 to 17

    • Disitimab vedotin US clinical trials from 23 to 26

October 2022 ​

  • All the links have been checked and were working properly.

  • The number of current clinical trials was updated accordingly.

    • Cytarabine Chinese clinical trials from 43 to 45​

    • Vidarabine US clinical trials from 49 to 48

    • Erubilin mesylate US clinical trials from 36 to 38

    • Brentuximab vedotin US clinical trials from 74 to 73 and European clinical trials from 42 to 40

    • Trabectedin US clinical trials from 22 to 21

    • Enfortumab vedotin US clinical trials from 17 to 18

    • Lurbinectedin US clinical trials from 18 to 17

    • Belantamab mafodotin US clinical trials from 29 to 31

    • Disitimab vedotin US clinical trials from 20 to 23 and Chinese clinical trials from 1 to 3

September 2022 

© 2021-2024 Marine Pharmacology
bottom of page